AUMED a.s. was established in 2007 and is now mainly engaged in research and development.. Its original focus has gradually begun to focus on the healthcare and pharmaceutical industries, where research and development activities are absolutely necessary due to new market requirements.

The company AUMED, a.s. focuses primarily on three research and development activities, specifically on the research and development of immunobiological preparations such as bacterial vaccines and immunomodulators, and then on the issue of bacteriophages. We build upon a nearly century-long tradition of Czech immunobiological and vaccine research and production. Our know-how is the result of a generationally-built legacy, with roots tracing back to the beginnings of the Czechoslovak Republic. In recent years, the company has registered increased interest, especially from foreign business partners, in alternative medicinal products that would replace the current massive use of antibiotics.

Under the company AUMED, a.s. also include the subsidiaries AUMED Immunology a.s. and Aumed Pharma a.s.. AUMED Immunology a.s. was founded with the aim of registering and launching a new medicinal product containing transfer factor as an active ingredient in the form of an oral lyophilized tablet. Aumed Pharma a.s. is engaged in the development of its unique cosmetic products, including the Phage Glow brand.